HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $7

-2.63% Pre

OCUGEN INC

OCGN

0.00

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ: OCGN) with a Buy and lowers the price target from $8 to $7.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

London's FTSE 100 steadies after four-day slide; inflation data boosts rate cut bets

Truist Securities Maintains Buy on Eli Lilly, Raises Price Target to $1182

A Look at Zymeworks (ZYME) Valuation After Breakthrough Phase 3 Cancer Trial Results

A Closer Look at Johnson & Johnson's Options Market Dynamics

BRIEF-Addex Therapeutics Ltd Files For Stock Shelf Of Up To $150 Million - SEC Filing

Patent Uncertainty and Drug Launch Timing Poise a Pivotal Question for Corcept Therapeutics (CORT)

JP Morgan Initiates Coverage On OPKO Health with Neutral Rating

MediWound Q3 EPS $(0.24) Beats $(0.81) Estimate, Sales $5.429M Miss $6.646M Estimate